Trading Analysis Report: PATH
- Analysis date: 2026-06-01
- Processed decision: Buy
- Price Target: 14
I. Analyst Team Reports
Market Analyst
Market Report
UiPath (PATH) traded at $11.72 on May 29, 2026. yfinance showed a 52-week range of $9.20-$19.84, a 50-day average of $10.72, and a 200-day average of $13.00.
The stock remains weak despite better operating execution. The local yfinance history showed a -11.9% one-year return and -26.2% YTD return.
PATH fits the AI queue directly because UiPath is an enterprise automation and agentic business orchestration software company. Its platform combines automation, AI, machine learning, process orchestration, document understanding, communications mining, testing, and integrations.
Market read: Buy with a $14 target. The target is modestly above the yfinance mean analyst target of $13.31 and median target of $13.00, reflecting improving profitability and cash flow without assuming a large growth re-rating.
Sentiment Analyst
Sentiment Report
Sentiment improved after Q1 FY2027 results.
Q1 FY2027 revenue was $418 million, up 17% year over year. ARR was $1.901 billion as of April 30, 2026, up 12% year over year, and net new ARR was $49 million.
Dollar-based net retention was 109%, GAAP gross margin was 82%, and non-GAAP gross margin was 83%.
GAAP operating income was $28 million, and non-GAAP operating income was $92 million. Management said this was UiPath's first-ever first-quarter GAAP profitability.
Q1 net cash flow from operations was $132 million, and non-GAAP adjusted free cash flow was $130 million.
Sentiment read: Buy because profitability and cash generation improved while agentic automation products are moving from pilots to production.
News Analyst
News Report
The key current source is UiPath's May 28, 2026 Q1 FY2027 results release.
Management said customers are standardizing on UiPath as the orchestration and automation execution layer for enterprise AI transformation. The company also launched UiPath for Coding Agents.
Q2 FY2027 guidance calls for revenue of $395-$400 million, non-GAAP operating income of approximately $65 million, and ARR of $1.929-$1.934 billion as of July 31, 2026.
FY2027 guidance calls for revenue of $1.776-$1.781 billion, non-GAAP operating income of approximately $360 million, and ARR of $2.057-$2.062 billion as of January 31, 2027.
News read: UiPath has a credible agentic AI platform narrative, but the expected Q2 revenue range is below Q1 revenue, so the market will focus on ARR acceleration and agentic product adoption.
Fundamentals Analyst
Fundamentals Report
PATH fundamentals show high gross margin, net cash, and strong free cash flow.
yfinance showed market cap of approximately $6.10 billion, enterprise value of approximately $4.90 billion, total revenue of approximately $1.67 billion, operating cash flow of approximately $384.1 million, free cash flow of approximately $522.6 million, total cash of approximately $1.31 billion, and total debt of approximately $72.0 million.
The same snapshot showed revenue growth of 17.3%, gross margin of 83.1%, operating margin of 7.3%, profit margin of 19.6%, trailing P/E of 19.53x, forward P/E of 12.98x, and price/sales of 3.65x.
The FY2026 10-K describes UiPath's enterprise automation platform as combining RPA, AI, ML, process orchestration, document understanding, communications mining, testing, and integration capabilities.
Fundamental read: Buy because valuation is reasonable for a profitable AI automation software company with net cash and strong free cash flow, but growth and retention are not yet strong enough for an aggressive target.
II. Research Team Decision
Bull Researcher
Bull Research
The bull case is that UiPath is moving from RPA into agentic business orchestration at the exact time enterprises are trying to operationalize AI.
Q1 revenue grew 17%, ARR grew 12%, GAAP operating income was positive, non-GAAP operating income was $92 million, and adjusted free cash flow was $130 million.
The balance sheet is strong. Cash, cash equivalents, and marketable securities were $1.42 billion as of April 30, 2026, and yfinance showed only approximately $72.0 million of total debt.
If agentic products move from pilot to production and UiPath becomes the automation execution layer for enterprise AI, ARR can reaccelerate and the multiple can expand.
Bull conclusion: PATH can work if agentic automation adoption drives better ARR growth and net retention.
Bear Researcher
Bear Research
The bear case is that growth is still only moderate for an AI software name.
ARR grew 12%, dollar-based net retention was 109%, and Q2 revenue guidance of $395-$400 million is below Q1 revenue of $418 million. That could limit near-term enthusiasm.
The stock is below the $13.00 200-day average and still down 26.2% YTD in the local yfinance history, showing investor skepticism.
The 10-K risk framework includes competition from enterprise software and AI platform vendors, slower automation spending, adoption and expansion risk, renewal and net retention risk, strategic acquisition execution, cybersecurity, international operations, stock-based compensation, restructuring, and macro uncertainty.
Bear conclusion: PATH could stay range-bound if agentic AI adoption does not translate into faster ARR growth.
Research Manager
Research Manager Synthesis
The bull case is direct AI exposure, agentic automation, first-quarter GAAP profitability, strong free cash flow, net cash, and reasonable valuation.
The bear case is moderate ARR growth, 109% retention, sequentially lower Q2 revenue guidance, and competition from larger AI and enterprise software platforms.
The correct conclusion is Buy with a modest target. The $14 target is only slightly above consensus because the company must show ARR acceleration before a bigger re-rating is justified.
Synthesis: assign Buy with a $14 target.
III. Trading Team Plan
Trader
Trader View
PATH is above the $10.72 50-day average but below the $13.00 200-day average.
Upside trigger: Q2 revenue above $400 million, ARR above $1.934 billion, stronger net new ARR, dollar-based net retention moving above 110%, or major agentic automation production wins.
Downside trigger: Q2 revenue below $395 million, ARR below $1.929 billion, weaker retention, slower enterprise AI automation adoption, or competitive pressure from large platform vendors.
Trading plan: Buy with a $14 6-12 month base-case target and reassess if ARR growth fails to accelerate.
IV. Risk Management Team Decision
Aggressive Analyst
Aggressive Risk View
Aggressive investors can buy PATH for direct agentic AI automation exposure and operating leverage.
The risk is that the market may demand faster ARR growth than the current 12% rate before paying a higher multiple.
Aggressive conclusion: Buy.
Conservative Analyst
Conservative Risk View
Conservative investors should recognize that PATH has net cash and free cash flow, but growth is not yet exceptional.
The right sizing is moderate until ARR and retention improve.
Conservative conclusion: Hold to small Buy.
Neutral Analyst
Neutral Risk View
The neutral view is constructive.
UiPath is a real AI automation platform, but the next leg needs proof that agentic products drive reacceleration.
Neutral conclusion: Buy with a modest target.
V. Portfolio Manager Decision
Portfolio Manager
Portfolio Manager Decision
Rating: Buy Price Target: 14
Horizon: 6-12 months Current Price Reference: $11.72 on 2026-05-29
UiPath is rated Buy. PATH is included in the web-researched AI queue because it is a direct enterprise AI and automation software company. Its platform combines robotic process automation, AI, machine learning, process orchestration, document understanding, communications mining, testing, and integrations. The strategic pitch is that UiPath becomes the orchestration and automation execution layer for enterprise AI transformation.
The latest major financial update is Q1 FY2027 results. Revenue was $418 million, up 17% year over year. ARR was $1.901 billion as of April 30, 2026, up 12% year over year, and net new ARR was $49 million. Dollar-based net retention was 109%.
Margins and cash flow improved. GAAP gross margin was 82%, non-GAAP gross margin was 83%, GAAP operating income was $28 million, and non-GAAP operating income was $92 million. Management said this was UiPath's first-ever first-quarter GAAP profitability.
Q1 net cash flow from operations was $132 million, and non-GAAP adjusted free cash flow was $130 million. Cash, cash equivalents, and marketable securities were $1.42 billion as of April 30, 2026.
Q2 FY2027 guidance calls for revenue of $395-$400 million, non-GAAP operating income of approximately $65 million, and ARR of $1.929-$1.934 billion as of July 31, 2026. FY2027 guidance calls for revenue of $1.776-$1.781 billion, non-GAAP operating income of approximately $360 million, and ARR of $2.057-$2.062 billion as of January 31, 2027.
yfinance showed a latest price of $11.72, market cap of approximately $6.10 billion, enterprise value of approximately $4.90 billion, 52-week range of $9.20-$19.84, total revenue of approximately $1.67 billion, revenue growth of 17.3%, gross margin of 83.1%, operating margin of 7.3%, profit margin of 19.6%, operating cash flow of approximately $384.1 million, free cash flow of approximately $522.6 million, total cash of approximately $1.31 billion, total debt of approximately $72.0 million, trailing P/E of 19.53x, forward P/E of 12.98x, price/sales of 3.65x, mean analyst target of $13.31, and median analyst target of $13.00.
The main risks are competition from enterprise software and AI platform vendors, slower automation spending, customer adoption and expansion risk, renewal and net retention risk, execution of acquisitions and product transitions, cybersecurity, international operations, stock-based compensation, restructuring, and macroeconomic uncertainty.
The $14 target reflects direct AI automation exposure, improved profitability, strong free cash flow, and a net cash balance. Buy is appropriate, but the target is modest because ARR growth of 12% and retention of 109% must improve before PATH deserves a larger AI software re-rating.